NEUROMYELITIS OPTICA SPECTRUM DISORDER

This study tests a drug called satralizumab in children aged 2 to 11 with a rare disease called NMOSD, which causes inflammation in the nerves and spinal cord. The goal is to see how the drug works in the body, whether it is safe, and if it can prevent relapses. Only 8 children w…

This study tests a drug called inebilizumab in children aged 2 to 17 with neuromyelitis optica spectrum disorder (NMOSD), a rare disease that causes inflammation in the eyes and spinal cord. The goal is to see how the drug moves through the body, how safe it is, and whether it ca…

This study tests a medicine called ravulizumab in children with neuromyelitis optica spectrum disorder (NMOSD), a rare disease where the immune system attacks the nerves. The goal is to see if the drug can reduce the number of relapses (flare-ups) and slow disability. About 12 ch…

This small pilot study tests whether ofatumumab can reduce the number of relapses in people with a rare autoimmune disease called NMOSD. The study enrolls 5 adults who have had at least 2 relapses in the past 2 years. Researchers will track relapse rates and disability scores ove…

This study is a French registry that follows 1,500 pregnant women with multiple sclerosis (MS) or related conditions, along with their children. The goal is to learn how the disease and medications used during pregnancy affect both mother and child. Researchers will track relapse…

This study is a long-term registry for adults with AQP4+ neuromyelitis optica spectrum disorder (NMOSD) who are already taking Alexion C5 inhibitor drugs (eculizumab or ravulizumab) to prevent relapses. Researchers will collect data on relapse rates, safety, and quality of life o…

This study follows 60 women with neuromyelitis optica spectrum disorder (NMOSD) who received UPLIZNA during pregnancy or within six months before conceiving. Researchers will collect data on pregnancy outcomes, including birth defects, preterm birth, and infant development over 1…